We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

FAP

Fibroblast activation protein (FAP) inhibitors and ligands target a protease of activated fibroblasts. FAP was described in 1990 as a cell surface glycoprotein of reactive stromal fibroblasts in human epithelial cancers. Its cloning in 1994 placed it in the serine protease family, close to dipeptidyl peptidase IV (DPP-IV). FAP cleaves peptides after proline residues, both as a dipeptidyl peptidase and as an endopeptidase. Ac-Gly-BoroPro and talabostat are boronic acid dipeptides, and talabostat also inhibits DPP-IV and related peptidases. FAPI-4, reported in 2018, is a quinoline-based FAP ligand developed for imaging research. Simlukafusp alfa is an immunocytokine that fuses an anti-FAP antibody to a variant interleukin-2 (IL-2).

1 Item

  • R-75317
    Cat. No.
    A62990
    CAS No.
    115406-25-2

    R-75317

    R-75317 is a selective antagonist of platelet-activating factor (PAF). It has demonstrated the ability to prevent the decline in creatinine clearance in a rat model of antibody-induced glomerulonephritis, delay the onset of proteinuria, and ameliorate glomerular hypertrophy, mesangial matrix proliferation, and interstitial fibrosis. This compound may serve as a valuable tool in the investigation of glomerulonephritis and related renal pathologies.

    In stock View Details
    25 mg
    $1,405.00
    50 mg
    $1,790.00
    All 3 sizes

1 Item

Added to your cart

View Cart Checkout

    Loading...